Trials / Available

AvailableNCT07536815

An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)

Status: Available
Phase: —
Study type: Expanded Access
Enrollment: —

Sponsor: CytoDyn, Inc. · Industry
Sex: All
Age: 18 Years
Healthy volunteers: —

Summary

This Expanded Access Program provides investigational access to leronlimab (PRO 140) for patients with advanced or metastatic triple-negative breast cancer (TNBC) who lack satisfactory treatment options and are unable to participate in a clinical trial.

Conditions

TNBC
TNBC - Triple-Negative Breast Cancer
TNBC, Triple Negative Breast Cancer

Interventions

Type	Name	Description
DRUG	leronlimab (PRO 140)	Leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.

Timeline

First posted: 2026-04-17
Last updated: 2026-04-17

Source: ClinicalTrials.gov record NCT07536815. Inclusion in this directory is not an endorsement.